ACRS News and Press, Aclaris Therapeutics Inc. From 03/06/23

2023-03-06 08:36:42 ET Aclaris Therapeutics ( NASDAQ: ACRS ) oral drug zunsemetinib (ATI-450) did not meet the main goal of a phase 2a trial in patients with with moderate to severe hidradenitis suppurativa (HS). HS is a condition which causes small, painful lumps ...

2023-03-06 08:17:23 ET Aclaris Therapeutics ( ACRS ) -38% after preliminary topline data from 12-week Phase 2a study did not meet primary or secondary efficacy endpoints in hidradenitis suppurativa . Esperion Therapeutics ( ESPR ) -27% amid Nexletol data ...

- Study Did Not Meet Primary or Secondary Efficacy Endpoints in Hidradenitis Suppurativa - Overall Safety Profile and PK/PD Generally Consistent with Observations in Prior Studies of Zunsemetinib WAYNE, Pa., March 06, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ...

Aclaris Therapeutics press release ( NASDAQ: ACRS ): Q4 GAAP EPS of -$0.41 beats by $0.05 . Revenue of $7.75M (+416.7% Y/Y) beats by $5.76M . As of December 31, 2022, Aclaris had aggregate cash, cash equivalents and marketable securities of $229.8 million compared to $...

WAYNE, Pa., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year of 2022 and ...

WAYNE, Pa., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fires...

The following slide deck was published by Aclaris Therapeutics, Inc. in conjunction with this event. For further details see: Aclaris Therapeutics (ACRS) Presents at the 41st Annual J.P. Morgan Healthcare Conference -- Slideshow

Summary Aclaris Therapeutics, Inc. stands out with a very interesting pipeline of treatments under development. The company's pipeline of treatments targets specific conditions resulting from autoimmune diseases. Some analysts see the possibility of good potential coming from the to...

WAYNE, Pa., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today is providing a corporate outlook for 2023. “2023 is setting up to be...

WAYNE, Pa. and SHANGHAI, China, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, and Pediatrix Therapeutics, Inc. (Pediatrix), a pediatrics-fo...